Publications by authors named "R Mouy"
Article Synopsis
- Activated monocytes contribute to chronic inflammatory diseases like Juvenile Idiopathic Arthritis (JIA), causing damage to joints and highlighting a need for new treatment strategies.
- The study investigated the histamine analog clobenpropit (CB) as a potential therapy targeting the CXCR4 receptor on monocytes, showing it reduces the production of inflammatory cytokines in both JIA patients and arthritic mice.
- CB treatment led to significant improvements in mouse models, decreasing inflammation and joint damage, suggesting it could be a promising therapeutic option alongside current treatments for rheumatoid arthritis.
Background: Some patients with systemic juvenile idiopathic arthritis (SJIA) and severe, refractory disease achieved remission through intensive immunosuppressive treatment followed by autologous hematopoietic stem cell transplantation (HSCT). However, disease relapsed in most cases. More recently selected SJIA patients received allogenic HSCT from a HLA-identical sibling or a HLA matched unrelated donor.
View Article and Find Full Text PDFArticle Synopsis
- A study examined the long-term safety and effectiveness of adalimumab in treating juvenile idiopathic arthritis (JIA) over 6 years, involving children aged 4-17 in a controlled trial.
- Results showed that while only 36% of participants completed the study, many achieved substantial improvements in their condition, with 63 patients reaching clinical remission during the trial.
- Overall, adalimumab was well tolerated and demonstrated significant therapeutic effects, although the retention rate among patients was relatively low.
Objectives: To assess the incidence rate and type of serious adverse events (SAE) in children with rheumatic inflammatory diseases treated with the interleukin 6 blocker tocilizumab (TCZ).
Methods: A retrospective review of all consecutive patients diagnosed with an inflammatory rheumatic disease and receiving at least one dose of TCZ was performed in two French tertiary pediatric rheumatology centers between 01/2007 and 06/2019. SAE were defined as a life-threatening event and/or an event requiring hospital admission, leading to permanent disability or treatment discontinuation.
A guideline group consisting of a pediatric rheumatologist, internists, rheumatologists, immunologists, a physiotherapist and a patient expert elaborated guidelines related to the management of juvenile dermatomyositis on behalf of the rare autoimmune and autoinflammatory diseases network FAIR. A systematic search of the literature published between 2000 and 2015 and indexed in PubMed was undertaken. Here, we present the expert opinion for diagnosis and treatment in juvenile dermatomyositis.
View Article and Find Full Text PDF